Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
June 12, 2019 Off

Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

By BusinessWire

SAN DIEGO & CAMBRIDGE, England–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration…

June 12, 2019 Off

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

By BusinessWire

WOBURN, Mass.–(BUSINESS WIRE)–CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand…

June 12, 2019 Off

Macrogen Announces Strategic Investment in Australian Microbiome Company, Microba

By BusinessWire

Share subscription agreement of 4.1million AUD with Microba Microbiome database construction in Asia Pacific region within the year, followed by…

June 12, 2019 Off

Syros Announces Appointment of Alice T. Shaw to its Board of Directors

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of genes,…

June 12, 2019 Off

X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

By BusinessWire

Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies…

June 12, 2019 Off

Syros to Present at JMP Securities Life Sciences Conference

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced…

June 12, 2019 Off

Aimmune to Present at the JMP Securities Life Sciences Conference

By BusinessWire

BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President…

June 12, 2019 Off

Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor

By BusinessWire

Results to be Presented During a Late-Breaking Oral Session at the Annual European Congress of Rheumatology (EULAR 2019) NEW YORK–(BUSINESS…

June 12, 2019 Off

Prelude Therapeutics Secures $60 Million and Expands Management Team to Develop Drugs Targeting Novel Molecular Mechanisms in Cancer

By BusinessWire

– Advances lead product into clinic and additional compounds into preclinical development – David Mauro, MD, PhD, as Chief Medical…

June 12, 2019 Off

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML)

By BusinessWire

-Data Presentations Highlight Continued Advances in Research for Treating Blood Cancers- BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data…

Posts pagination

Previous 1 … 3,102 3,103 3,104 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine